Glioblastoma Multiforme is one of the deadliest cancers in all of oncology with a sudden onset of symptoms and life expectancy of about one year. It offers a small commercial market opportunity, but a disproportionately large pot of investor gold. This is because a commercial foothold here validates a company's entire process and pipeline, allowing them to grow an asymmetrical amount of investor interest.
The balance of this year, and entirety of 2015 will reveal which of these four companies: Celldex (CLDX), CytRx (CYTR), Nektar Therapeutics (NKTR), and Northwest Biotherapeutics (NWBO) have the best chance of offering a commercially viable solution. There is, however, a clear division amongst these four companies favoring...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|